Literatur
http://clients.mediaondemand.net/pedersen/
Achenbach S, Ropers D, Pohle K et al. (2002) Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 106: 1077–1082
Pohle K, Maffert R, Ropers D et al. (2001) Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 104: 1927–1932
Novaro GM, Tiong IY, Pearce GL et al. (2001) Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104: 2205–2209
Shavelle DM, Takasu J, Budoff MJ et al. (2002) HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 359: 1125–1126
Aronow WS, Ahn C, Kronzon I, Goldman ME (2001) Association of coronary risk factors and the use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88: 693–695
Bellamy MF, Pellikka PA, Klarich KW et al. (2002) Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 40: 1723–1730
Cowell SJ, Newby DE, Prescott RJ et al. (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352: 2389–2397
Cholesterol Treatment Trialists‘ (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Graf, K. Überraschende Ergebnisse der SEAS-Studie. Kardiologe 2, 403–405 (2008). https://doi.org/10.1007/s12181-008-0117-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12181-008-0117-6